β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis
Open Access
- 16 February 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 69 (6), 1441-1446
- https://doi.org/10.1093/jac/dku033
Abstract
Several studies have compared the clinical effect of β-lactam/macrolide (BLM) dual therapy versus β-lactam (BL) monotherapy in community-acquired pneumonia (CAP) patients. However, the results remain controversial. Thus, we did this meta-analysis to determine which treatment was more effective. Databases comprising PubMed, Embase and the Cochrane Register of Controlled Trials were searched to find relevant studies. The primary outcome was mortality. The Newcastle–Ottawa scale was used to evaluate the methodological quality of included studies. Multivariable-adjusted ORs with 95% CIs were pooled in the random effects model. Four prospective cohort studies and 12 retrospective cohort studies were included (n = 42 942). Compared with BL monotherapy, BLM dual therapy was significantly associated with reduced mortality (adjusted OR 0.67, 95% CI 0.61–0.73, P < 0.001, I2 = 3%). Subsequent subgroup analyses confirmed that BLM dual therapy was statistically superior to BL monotherapy in reduction of mortality. Sensitivity analyses strengthened the validity of the results. In comparison with BL monotherapy, BLM dual therapy might reduce mortality risk in patients with CAP. Because this finding is based on observational studies, randomized controlled trials are required to demonstrate the usefulness of BLM dual therapy in the treatment of CAP.Keywords
This publication has 30 references indexed in Scilit:
- BTS guidelines for the management of community acquired pneumonia in adults: update 2009Thorax, 2009
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Addition of a macrolide to a ß-lactam in bacteremic pneumococcal pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2006
- Impact of initial antibiotic choice on mortality from pneumococcal pneumoniaEuropean Respiratory Journal, 2006
- Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent aloneEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Addition of a Macrolide to a β‐Lactam–Based Empirical Antibiotic Regimen Is Associated with Lower In‐Hospital Mortality for Patients with Bacteremic Pneumococcal PneumoniaClinical Infectious Diseases, 2003
- Monotherapy May Be Suboptimal for Severe Bacteremic Pneumococcal PneumoniaArchives of Internal Medicine, 2001
- Empiric Antibiotic Therapy and Mortality Among Medicare Pneumonia Inpatients in 10 Western StatesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2001
- Antimicrobial Selection for Hospitalized Patients with Presumed Community-Acquired Pneumonia: A Survey of Nonteaching US Community HospitalsAnnals of Pharmacotherapy, 2000
- Associations Between Initial Antimicrobial Therapy and Medical Outcomes for Hospitalized Elderly Patients With PneumoniaArchives of Internal Medicine, 1999